Trial
NCT01829477
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Takeda
Collaborators
—
Condition
Diabetes Mellitus, Type 2
Intervention
TAK-875
Why stopped
Due to potential concerns about liver safety (See Detailed Description)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-01